Home › Funds › Parkman Healthcare Partners LLC › IMNM
Parkman Healthcare Partners LLC position in IMNM
IMMUNOME INC · Health Care
Parkman Healthcare Partners LLC reported holding 594,202 shares of IMNM (IMMUNOME INC) in its Q2 2026 13F filing — a position valued at US$12.6M, representing 1.29% of its reported portfolio and ranking #32 among its reported holdings. Parkman Healthcare Partners LLC has disclosed IMNM holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Parkman Healthcare Partners LLC's IMNM position evolved
Parkman Healthcare Partners LLC first disclosed a stake in IMNM in Q3 2025 at 351,131 shares (US$4.1M). The position peaked in Q2 2026 at 594,202 shares, worth US$12.6M. Across 4 filings, Parkman Healthcare Partners LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 594,202 shares valued at US$12.6M — an increase of 190,715 shares quarter over quarter.. Notable position changes include a 45% increase in Q1 2026 (shares fell 3% over the following quarter), a 47% increase in Q2 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 351.13K | $4.11M | New |
| Q4 2025 | 277.81K | $5.97M | Reduce |
| Q1 2026 | 403.49K | $8.82M | Add |
| Q2 2026 | 594.20K | $12.59M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IMNM and 13F data
IMNM (IMMUNOME INC) is a Health Care company. 48 other funds we track also report a position in IMNM — the largest reported positions include Redmile Group, LLC (US$104.1M), Enavate Sciences GP, LLC (US$76.6M), SILVERARC CAPITAL MANAGEMENT, LLC (US$42.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IMNM
- Redmile Group, LLC 4.91M sh · $104.08M · Q2 2026
- Enavate Sciences GP, LLC 3.61M sh · $76.58M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 2.02M sh · $42.74M · Q2 2026
- Sofinnova Investments, Inc. 1.72M sh · $36.45M · Q2 2026
- READYSTATE ASSET MANAGEMENT LP 1.61M sh · $34.03M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 732.51K sh · $15.52M · Q2 2026
- NAN FUNG TRINITY (HK) Ltd 714.55K sh · $15.14M · Q2 2026
- ALERUS FINANCIAL NA 383.42K sh · $8.12M · Q2 2026
- Atom Investors LP 297.49K sh · $6.30M · Q2 2026
More on Parkman Healthcare Partners LLC
FAQ
How long has Parkman Healthcare Partners LLC held IMNM?
Parkman Healthcare Partners LLC has disclosed IMNM holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Parkman Healthcare Partners LLC's current position in IMNM?
As of Q2 2026, Parkman Healthcare Partners LLC holds 594.20K shares of IMNM (IMMUNOME INC), valued at $12.59M, representing 1.29% of its reported portfolio and ranking #32.
Has Parkman Healthcare Partners LLC been buying or selling IMNM?
In the latest 13F filing (Q2 2026), Parkman Healthcare Partners LLC increased its position in IMNM. The position peaked in Q2 2026 at 594.20K shares.
Which other funds hold IMNM?
Other major institutional holders of IMNM include Redmile Group, LLC, Enavate Sciences GP, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.